Pricing Log in Create free account
Tuesday 13 October 2026 Export ARVN’s income statement to Excel — free account

Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.14 0.31 −4.16%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.27
Total sells 1.42
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — 1 — — — — — — —
Sell 1 — — 9 1 — 6 2 — — — —
Insider Ownership 9.57%

Capital & Financial Ratios $m

Market Cap 487.13
Revenue 316.70
Net Income 9.30
Free Cash Flow (208.80)
Net Debt (567.60)
Current Ratio 7.91 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 57.31 (above 35: high)
Fwd P/E (2.68) (negative: loss-making)
P/S ratio 1.52
P/B ratio 0.86
Past 5Y EPS Growth —
This Y EPS Growth 96.43% (at or above 15%: strong)
Next Y EPS Growth (8,053.92%) (below 0%: weak)
Next Y revenue growth 12.76% (at or above 10%: strong)
Next 5Y EPS Growth (23.43%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 8.6×; over the ten years it ranged from −4.5× in 2018 to 174× in 2021.
P/S against its own 10 years 5.15%
10-year low 10-year high
P/B against its own 10 years 3.37%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,267 1,039 685 568
Receivables 7 14 6 54
Inventory — — — —
Other — — — —
1,280 1,067 701 652
2023 2024 2025 Q'26
Payables 92 72 70 52
ST’ Debt — — — —
Other — — — 28
257 230 143 83

Compound Annual Growth %

10y 5y 3y
Sales — 58.93% 25.96%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.54%) (8.42%)

Revenue $m

Mar Jun Sep Dec Year
’26 16 250 — — —
’25 189 22 42 10 263
’24 25 77 102 59 263
’23 33 55 35 (43) 79
’22 27 34 33 38 131
’21 6 6 9 33 54
’20 6 6 8 6 26
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (69) (48) — — —
’25 (89) (95) (59) (30) (274)
’24 (97) 50 (128) (84) (259)
’23 (91) (89) (85) (83) (348)
’22 (57) (79) (67) (71) (273)
’21 (39) (47) 682 (36) 559
’20 (17) (21) (22) (29) (90)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (70) (48) — — —
’25 (89) (97) (59) (31) (276)
’24 (98) 50 (129) (84) (261)
’23 (92) (89) (86) (83) (351)
’22 (59) (80) (69) (72) (280)
’21 (40) (48) 680 (38) 555
’20 (18) (23) (24) (31) (96)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.90) 2.58 — — —
’25 1.14 (0.84) (0.48) (1.10) (1.14)
’24 (0.97) (0.49) (0.68) (0.63) (2.77)
’23 (1.54) (1.25) (1.18) (2.53) (6.62)
’22 (1.20) (1.32) (1.24) (1.56) (5.31)
’21 (0.84) (1.03) (0.94) (1.00) (3.82)
’20 (0.56) (0.65) (0.79) (0.99) (3.02)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 10.19 12.29 19.68 56.59 31.54 13.57 17.37 5.90

Analyst estimates 2026–2028

Powerpack
High — — 21.25 44.97 86.44 108.47 82.86 42.84 53.08 21.00
People
People Employees — 72 83 133 179 280 415 445 430 246
Revenue/emp, $m 0.00 0.11 0.17 0.32 0.14 0.19 0.32 0.18 0.61 1.07
Income, $m
Income, $m Revenue 7 8 14 43 26 54 131 79 263 263
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (14) (24) (41) (46) (115) (184) (251) (364) (198) (80)
EBT margin, % (216.50) (317.32) (289.59) (106.05) (444.79) (343.47) (191.02) (463.57) (75.28) (30.65)
Net income (14) (24) (41) (70) (119) (191) (282) (367) (199) (81)
Depreciation 1 1 1 3 6 16 16 (9) (11) (3)
Per share, $
Per share, $ Revenue 3.51 4.00 1.52 1.31 0.66 1.07 2.47 1.41 3.66 3.70
Earnings (7.56) (12.68) (25.45) (2.13) (3.02) (3.82) (5.31) (6.62) (2.77) (1.14)
Cash flow (10.22) 2.70 (1.71) (1.23) (2.27) 11.19 (5.14) (6.27) (3.61) (3.86)
Capex (0.14) (0.53) (0.30) (0.19) (0.16) (0.09) (0.13) (0.05) (0.02) (0.03)
Free cash flow (10.36) 2.16 (2.01) (1.43) (2.43) 11.09 (5.27) (6.32) (3.63) (3.89)
Book value 12.66 0.13 14.50 6.89 16.26 15.63 10.62 11.89 7.81 6.12
Shares, m 2 2 9 33 40 50 53 56 72 71
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 8.45 31.44 129.53 76.62 13.51 32.30 5.23 3.20
P/B 0.00 0.00 0.89 5.96 5.22 5.25 3.14 3.84 2.45 1.94
EV/Sales 0.00 0.00 (4.51) 24.97 103.06 48.54 4.31 16.20 1.29 0.60
EV/FCF (0.46) (0.46) 3.41 (22.89) (27.77) 4.69 (2.02) (3.63) (1.31) (0.57)
Cash, $m
Cash, $m Operating cash flow (19) 5 (16) (41) (90) 559 (273) (348) (259) (274)
Capex 0 (1) (3) (6) (6) (5) (7) (3) (2) (2)
Free cash flow (20) 4 (19) (47) (96) 555 (280) (351) (261) (276)
Balance, $m
Balance, $m Working capital 27 48 173 258 654 1,291 945 1,023 838 558
Total debt 0 0 2 2 2 1 1 1 1 0
Net debt (35) (39) (186) (279) (687) (1,506) (1,210) (1,266) (1,039) (685)
Shareholders’ equity 24 0 137 227 642 782 565 660 562 434
Returns, %
Returns, % ROA (23.54) (54.63) (180.25) (28.07) (23.41) (16.62) (19.82) (28.55) (16.60) (8.93)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE 26.32 60.82 (635.93) (38.70) (27.46) (26.83) (41.96) (59.97) (32.56) (16.23)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Arvinas, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OCS Oculis Holding AG $514.9M — (loss-making) — (loss-making) +23.96% (above 0%: growing) n/m −10.40% (below 0%: shrinking) 100.00% (7,603.42%) Compare
ALT Altimmune, Inc. $507.7M — (loss-making) — (loss-making) +520.00% (above 0%: growing) n/m −25.27% (below 0%: shrinking) 100.00% 0.00% Compare
ALLO Allogene Therapeutics, Inc. $504.4M — (loss-making) — (loss-making) +20,990.91% (above 0%: growing) n/m +17.73% (above 0%: growing) 100.00% (1,011.21%) Compare
CTNM Contineum Therapeutics, Inc. $503.4M — (loss-making) — — n/m +26.73% (above 0%: growing) 100.00% 0.00% Compare
ARVN Arvinas, Inc. $499.6M 57.3× — (loss-making) +1,014.73% (above 0%: growing) n/m +49.79% (above 0%: growing) 96.40% 65.72%
EPRX Eupraxia Pharmaceuticals Inc. $491.7M — (loss-making) — — n/m −56.41% (below 0%: shrinking) — 0.00% Compare
MPLT MapLight Therapeutics, Inc. $490.7M — (loss-making) — — n/m −31.91% (below 0%: shrinking) — 0.00% Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $481.8M — (loss-making) — (loss-making) +118.37% (above 0%: growing) n/m +67.55% (above 0%: growing) 55.20% (95.95%) Compare
OVID Ovid Therapeutics $480.4M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
Median of peers $497.5M — — +463.85% — −17.83% 100.00% (47.97%)

All 614 Biotechnology stocks →

Arvinas, Inc. (ARVN) key facts

  • Arvinas, Inc. (ARVN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.
  • As of October 12, 2026, ARVN traded at $7.45, a market capitalization of $487.1 million.
  • Return on equity was −16.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.61 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Arvinas, Inc. (ARVN) Latest News

9 Sep

Impact 5 ·

4 May

Impact 5 ·

1 May

Impact 5 ·
stockrow.com/ARVN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com